Antengene announces xpovio® plus bortezomib and dexamethasone included for reimbursement by the pbs in australia for the treatment of relapsed and/or refractory multiple myeloma

-  xpovio® (selinexor) is the first and only selective inhibitor of nuclear export (sine) inhibitor approved by the therapeutic goods administration (tga) of australia for patients with relapsed and/or refractory multiple myeloma (r/r mm) and in triple class refractory r/r mm. -  this inclusion by the pharmaceutical benefits scheme (pbs) for the treatment of patients with r/r mm who have received at least one prior therapy is the second inclusion of xpovio® by the pbs.
KPTI Ratings Summary
KPTI Quant Ranking